LONDON, Feb 3 (Reuters) - CanSino Biologics (6185.HK) Chief Executive Yu Xuefeng said on Friday he was confident his company's experimental COVID-19 vaccine using messenger RNA (mRNA) technology was as good as shots from Moderna and Pfizer-BioNTech.
China's CanSino reports 'positive' interim data from COVID mRNA booster trial
Beijing: Beijing residents can start making appointments for an inhalable COVID ..
CanSino Biologics Inc has announced that the National Medical Products Administration of China (NMPA) has granted the company approval for its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for inhalation (Convidecia Air) to be used as a booster dose.
Hong Kong: China's CanSino Biologics Inc said on Sunday that its recently developed COVID-19 vaccine has been approved by the country's drug regulator for emergency use as a booster, potentially benefiting its business.
Beijing: China's CanSino Biologics reported a 69.5% drop in revenue for the first six months versus a year ago, joining global and domestic COVID-19 vaccine makers affected by waning demand for their shots.
(Yicai Global) Aug. 1 -- CanSino Biologics’ inhalation-based Covid-19 vaccine has been shown to produce antibodies specific to the omicron BA.1 variant that remain in the body for more than half a year when administered as a heterologous booster shot, which is the use of a different type of vaccine following a regular course of another jab, according to the Chinese vaccine maker.
CanSinoBIO's inhaled COVID booster stronger against BA.1 Omicron subvariant than Sinovac shot